Mistakes That Make Investors Nervous, According to a PhD in Pitching

About this episode

There is no such thing as the perfect pitch. But you can get close by implementing a few research-backed methods to your delivery, deck, and message. In this episode of Build Mode, host Isabelle Johannesen sits down with Dr. Eike Gerhardt, who has aPhD in pitching and spent nearly a decade studying the science of startup pitching before starting Autopoiesis Sciences. And he’s joined by Demetri Maxim, co-founder and CEO of Nephrogen, who came in second at TechCrunch Startup Battlefield 2025. Together, they break down Demetri’s actual Startup Battlefield pitch to unpack what worked, what could be improved, and what research tells us about how investors respond to founders. Eike explains why credibility signals matter, how technical founders can simplify without oversimplifying, and why Q&A should be treated as a second pitch. Demetri shares how he learned to explain complex biotech to generalist investors, how redesigning his deck changed his confidence onstage, and what he would do differently today. They also explore how body language and authenticity affect a pitch, how investor questions can reveal bias, and how founders can use AI to prepare for difficult Q&A. They get into: